We have located links that may give you full text access.
Multimodality imaging using proton magnetic resonance spectroscopic imaging and (18)F-fluorodeoxyglucose-positron emission tomography in local prostate cancer.
World Journal of Radiology 2017 March 29
AIM: To assess the relationship using multimodality imaging between intermediary citrate/choline metabolism as seen on proton magnetic resonance spectroscopic imaging ((1)H-MRSI) and glycolysis as observed on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) in prostate cancer (PCa) patients.
METHODS: The study included 22 patients with local PCa who were referred for endorectal magnetic resonance imaging/(1)H-MRSI (April 2002 to July 2007) and (18)F-FDG-PET/CT and then underwent prostatectomy as primary or salvage treatment. Whole-mount step-section pathology was used as the standard of reference. We assessed the relationships between PET parameters [standardized uptake value (SUVmax and SUVmean)] and MRSI parameters [choline + creatine/citrate (CC/Cmax and CC/Cmean) and total number of suspicious voxels] using spearman's rank correlation, and the relationships of PET and (1)H-MRSI index lesion parameters to surgical Gleason score.
RESULTS: Abnormal intermediary metabolism on (1)H-MRSI was present in 21/22 patients, while abnormal glycolysis on (18)F-FDG-PET/CT was detected in only 3/22 patients. Specifically, index tumor localization rates were 0.95 (95%CI: 0.77-1.00) for (1)H-MRSI and 0.14 (95%CI: 0.03-0.35) for (18)F-FDG-PET/CT. Spearman rank correlations indicated little relationship (ρ = -0.36-0.28) between (1)H-MRSI parameters and (18)F-FDG-PET/CT parameters. Both the total number of suspicious voxels (ρ = 0.55, P = 0.0099) and the SUVmax (ρ = 0.46, P = 0.0366) correlated weakly with the Gleason score. No significant relationship was found between the CC/Cmax, CC/Cmean or SUVmean and the Gleason score (P = 0.15-0.79).
CONCLUSION: The concentration of intermediary metabolites detected by (1)H MRSI and glycolytic flux measured (18)F-FDG PET show little correlation. Furthermore, only few tumors were FDG avid on PET, possibly because increased glycolysis represents a late and rather ominous event in the progression of PCa.
METHODS: The study included 22 patients with local PCa who were referred for endorectal magnetic resonance imaging/(1)H-MRSI (April 2002 to July 2007) and (18)F-FDG-PET/CT and then underwent prostatectomy as primary or salvage treatment. Whole-mount step-section pathology was used as the standard of reference. We assessed the relationships between PET parameters [standardized uptake value (SUVmax and SUVmean)] and MRSI parameters [choline + creatine/citrate (CC/Cmax and CC/Cmean) and total number of suspicious voxels] using spearman's rank correlation, and the relationships of PET and (1)H-MRSI index lesion parameters to surgical Gleason score.
RESULTS: Abnormal intermediary metabolism on (1)H-MRSI was present in 21/22 patients, while abnormal glycolysis on (18)F-FDG-PET/CT was detected in only 3/22 patients. Specifically, index tumor localization rates were 0.95 (95%CI: 0.77-1.00) for (1)H-MRSI and 0.14 (95%CI: 0.03-0.35) for (18)F-FDG-PET/CT. Spearman rank correlations indicated little relationship (ρ = -0.36-0.28) between (1)H-MRSI parameters and (18)F-FDG-PET/CT parameters. Both the total number of suspicious voxels (ρ = 0.55, P = 0.0099) and the SUVmax (ρ = 0.46, P = 0.0366) correlated weakly with the Gleason score. No significant relationship was found between the CC/Cmax, CC/Cmean or SUVmean and the Gleason score (P = 0.15-0.79).
CONCLUSION: The concentration of intermediary metabolites detected by (1)H MRSI and glycolytic flux measured (18)F-FDG PET show little correlation. Furthermore, only few tumors were FDG avid on PET, possibly because increased glycolysis represents a late and rather ominous event in the progression of PCa.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app